Deep Dive Into Elevance Health Stock: Analyst Perspectives (7 Ratings)

7 analysts have expressed a variety of opinions on Elevance Health ELV over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 0 7 0 0 0
Last 30D 0 1 0 0 0
1M Ago 0 1 0 0 0
2M Ago 0 1 0 0 0
3M Ago 0 4 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $565.57, a high estimate of $584.00, and a low estimate of $547.00. This current average has increased by 1.08% from the previous average price target of $559.50.

price target chart

Decoding Analyst Ratings: A Detailed Look

In examining recent analyst actions, we gain insights into how financial experts perceive Elevance Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Sarah James Cantor Fitzgerald Maintains Overweight $580.00 -
Andrew Mok Barclays Announces Overweight $584.00 -
Sarah James Cantor Fitzgerald Raises Overweight $580.00 $547.00
Sarah James Cantor Fitzgerald Maintains Overweight $547.00 -
Sarah James Cantor Fitzgerald Maintains Overweight $547.00 -
Ben Hendrix RBC Capital Raises Outperform $574.00 $572.00
Sarah James Cantor Fitzgerald Maintains Overweight $547.00 -

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Elevance Health. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Elevance Health compared to the broader market.
  • Price Targets: Gaining insights, analysts provide estimates for the future value of Elevance Health's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into Elevance Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Elevance Health analyst ratings.

Get to Know Elevance Health Better

Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 48 million medical members as of June 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.

Financial Insights: Elevance Health

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: Elevance Health displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 6.81%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.01%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Elevance Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.2%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Elevance Health's ROA stands out, surpassing industry averages. With an impressive ROA of 0.78%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Elevance Health's debt-to-equity ratio stands notably higher than the industry average, reaching 0.64. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

How Are Analyst Ratings Determined?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!